Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P44 versus Darzalex Faspro with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma
2024-518588-36-00Phase 3Authorised
- Sponsor
- Celltrion
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of CT-P44 in multiple myeloma (MM) (2 arms), sponsored by Celltrion. Primary endpoints: AUCWeek0-1 of daratumumab and AUCWeek8-10 of daratumumab. Planned start Dec 2025; status: authorised.
02
Drugs
CT-P44
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-518588-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518588-36-00.